Thomas Schirrmann Email & Phone Number

Brunswick, Nds, De

Operations, investor relations, second generation compounds COR-201

Braunschweig, Niedersachsen, De

Management, Strategy, Partnering

Development of COVID-19 antibody therapeutics; fast-track program; first financing round; definition of lead compound COR-101; initiation of CMC activities

Braunschweig, Niedersachsen, De

Research with focus on human antibody discovery and development, recombinant protein production, novel antibody formats, bispecific antibodies and therapeutic antibody fusion proteins, >70 publications, Coordination of the German NGFN2 project "Antibody Factory", Subprojects in EU FP7 "Affinity proteome" and "Affinomics"

Berlin, De

Research in immunology, tumor vaccination and targeting of immune cells with gene modified immune cells (CAR-NK)

Berlin, Berlin, De

Research in tumor immunology, gene therapy, cellular immunotherapy, Natural Killer (NK) cells, dendritic cells (DCs)

Phd, Dr. Rer. Nat., Immunologie

Diplom, Biochemie